These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34949146)

  • 1. JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016-present).
    Chen C; Lu D; Sun T; Zhang T
    Expert Opin Ther Pat; 2022 Mar; 32(3):225-242. PubMed ID: 34949146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
    He X; Chen X; Zhang H; Xie T; Ye XY
    Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.
    Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
    Expert Opin Ther Pat; 2017 Feb; 27(2):145-161. PubMed ID: 27774822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
    Norman P
    Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors.
    Dai J; Yang L; Addison G
    Mini Rev Med Chem; 2019; 19(18):1531-1543. PubMed ID: 31288716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.
    Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
    Expert Opin Ther Pat; 2017 Feb; 27(2):127-143. PubMed ID: 27774824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
    Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
    J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent patents in the discovery of small molecule inhibitors of JAK3.
    Wilson LJ
    Expert Opin Ther Pat; 2010 May; 20(5):609-23. PubMed ID: 20402545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
    Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
    Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
    Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
    J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
    Treliński J; Robak T
    Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712.
    Breinlinger E; Van Epps S; Friedman M; Argiriadi M; Chien E; Chhor G; Cowart M; Dunstan T; Graff C; Hardee D; Herold JM; Little A; McCarthy R; Parmentier J; Perham M; Qiu W; Schrimpf M; Vargo T; Webster MP; Wu F; Bennett D; Edmunds J
    J Med Chem; 2023 Oct; 66(20):14335-14356. PubMed ID: 37823891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docking and Selectivity Studies of Covalently Bound Janus Kinase 3 Inhibitors.
    Zhong HA; Almahmoud S
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021).
    Gonzalez Lopez de Turiso F; Guckian K
    Expert Opin Ther Pat; 2022 Apr; 32(4):365-379. PubMed ID: 35001782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
    Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
    Front Immunol; 2022; 13():884399. PubMed ID: 35693820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
    Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
    J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibitors of the Janus kinase Jak3--Are they effective?
    Thoma G; Drückes P; Zerwes HG
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abrocitinib: First Globally Approved Selective Janus Kinase-1 Inhibitor for the Treatment of Atopic Dermatitis.
    De SK
    Curr Med Chem; 2023; 30(38):4278-4282. PubMed ID: 36797599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal Epithelial Jak Kinases in Health and Diseases.
    Kumar N; Kuang L; Villa R; Kumar P; Mishra J
    Mediators Inflamm; 2021; 2021():6618924. PubMed ID: 33814980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.